Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T17:34:00.914Z.
Calculation as of: 2026-10-06T17:34:00.914Z.
Quote observation: 2026-10-06T17:29:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 960fabb584be58b0360682ce889880f50a04fda9407a8e289859ad1a2016d30f
EARNINGS YIELD
N/A
Market Cap
$188.55M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.94M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.71M
Earnings Yield
92.57%
TTM Avg
50.31%
3Y Avg
28.59%
5Y Avg
28.59%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | $191.67M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.55M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.35M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.32M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.71M | 92.57% | 50.31% | 28.59% | 28.59% |
| Alector, Inc. (ALEC)vs › | $203.98M | N/A | 3.98% | 3.98% | 3.98% |
| Yarrow Bioscience Inc (YARW)vs › | $178.50M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $205.31M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
